Celyad Oncology SA Celyad (NASDAQ: CYAD) Signs $40M Equity Purchase Agreement With Lincoln Park Capital Celyad Oncology SA (NASDAQ: CYAD) disclosed that it has signed an equity buying deal with Lincoln Park Capital. The Buying Contract which lasts for 24-months will allow Celyad to use the profit from sales of ADSs for the general purpose of the firm.
